Funder
Pharmaceutical Research and Manufacturers of America Foundation
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Aff (Millwood). 2009;28(5):1366–71. https://doi.org/10.1377/hlthaff.28.5.1366.
2. Centers for Medicare & Medicaid Services. Department of Health & Human Services. Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026. Available at: https://www.cms.gov/files/document/revised-medicare-drug-price-negotiation-program-guidance-june-2023.pdf. Accessed 6 Aug 2023.
3. Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force Report [3]. Value Health. 2018;21(2):131–9. https://doi.org/10.1016/j.jval.2017.12.007.
4. Dubois RW. WK. Value Assessment Frameworks: How Can They Meet The Challenge? Available at: https://www.healthaffairs.org/content/forefront/value-assessment-frameworks-can-they-meet-challenge. Published 2017. Accessed 6 Aug 2023.
5. Willke RJ, Neumann PJ, Garrison LP Jr, Ramsey SD. Review of recent US value frameworks-a health economics approach: an ISPOR Special Task Force Report [6]. Value Health. 2018;21(2):155–60. https://doi.org/10.1016/j.jval.2017.12.011.